Scientific Initiatives, Stock Price Movement, and Financial Results - Research Report on BMS, Actavis, LabCorp, Quest

Scientific Initiatives, Stock Price Movement, and Financial Results - Research
       Report on BMS, Actavis, LabCorp, Quest Diagnostics, and Novartis

PR Newswire

NEW YORK, October 23, 2013

NEW YORK, October 23, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting
Bristol-Myers Squibb Co. (NYSE: BMY), Actavis plc (NYSE: ACT), Laboratory
Corp. of America Holdings (NYSE: LH), Quest Diagnostics Inc. (NYSE: DGX), and
Novartis AG (ADR) (NYSE: NVS). Today's readers may access these reports free
of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Bristol-Myers Squibb Co. Research Report

On October 16, 2013, Bristol-Myers Squibb Co. (BMS) announced the launch of
Partnering for Cure, a scientific initiative to support education and research
to transform clinical outcomes for patients with chronic viral diseases, such
as HIV, hepatitis B (HBV), and hepatitis C (HCV). The announcement came in at
the 14th European AIDS Conference (EACS) in Brussels, Belgium. The Company
said that Partnering for Cure is led by an expert panel of clinical experts
from across Europe. It will be composed of three core components (education,
scientific exchange, and scientific research) and will focus on reviewing
current treatment paradigms, providing a forum for discussion on the evolution
of treatment towards cure and facilitating research seeking novel cure
pathways in chronic viral diseases. BMS reported that it will also support
three independent research projects focused on improving current
understandings of HIV, HBV and HCV, and creating novel treatment and cure
strategies, and the research applications will be accepted via the Company
website until October 31, 2013. The Full Research Report on Bristol-Myers
Squibb Co. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/81a9_BMY]

--

Actavis plc Research Report

On October 18, 2013, Actavis plc's (Actavis) stock rose marginally by 0.03%,
ending the day at $146.92. Over the previous three trading sessions, shares of
Actavis gained 4.54%, outperforming the S&P 500, which gained 2.73% during the
same period. The Full Research Report on Actavis plc - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.analystscorner.com/r/full_research_report/4997_ACT]

--

Laboratory Corp. of America Holdings Research Report

On October 18, 2013, Laboratory Corp. of America Holdings (LabCorp) reported
its Q3 2013 financial results. The Company's net sales increased 3.0% YoY to
$1.5 billion during the quarter. Net earnings attributable to LabCorp were
$148.3 million or $1.63 per diluted share in Q3 2013, compared to net earnings
attributable to LabCorp of $148.0 million or $1.53 per diluted share in Q3
2012. Adjusted EPS excluding amortization increased 2.3% YoY to $1.80. David
P. King, Chairman and CEO of LabCorp, said, "We are pleased with our third
quarter and year-to-date results, as we delivered another quarter of solid
revenue and volume growth. Government payment reductions and continued
reimbursement challenges for molecular testing negatively affected our
reported results in terms of revenue growth, price and margins. Despite these
challenges, we continue to execute our five pillar strategy and remain focused
on growing our business and returning capital to shareholders." The Full
Research Report on Laboratory Corp. of America Holdings - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.analystscorner.com/r/full_research_report/c267_LH]

--

Quest Diagnostics Inc. Research Report

On October 17, 2013, Quest Diagnostics, Inc. (Quest Diagnostics) reported its
Q3 2013 financial results. The Company's net revenues declined 1.9% YoY to
$1.8 billion during the quarter. Net income attributable to Quest Diagnostics
was $405.1 million or $2.68 per diluted share in Q3 2013, up compared to net
income attributable to Quest Diagnostics of $163.1 million or $1.01 per
diluted share in Q3 2012. Commenting on the results, Steve Rusckowski,
President and CEO of Quest Diagnostics, said, "We are disappointed with our
third quarter performance, particularly after generating revenues early in the
period that were in line with our expectations. Healthcare utilization and
reimbursement continue to be a headwind for our industry, and our results
reflect that. As we have said previously, 2013 is a building year that will
position us well for 2014 and beyond. We remain focused on executing our
five-point strategy." The Full Research Report on Quest Diagnostics Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/05ba_DGX]

--

Novartis AG (ADR) Research Report

On October 18, 2013, Bloomberg reported that Roche Holding AG's (Roche) CEO
Severin Schwan said that founding families of Roche wants the Company to stay
independent, in response to the speculation that circulated since a Novartis
AG (ADR) (Novartis) board member Pierre Landolt said in September 2013 that a
merger could make sense. The Bloomberg report also quoted what Schwan said in
a conference call with reporters, "Nothing has changed with regards to Roche's
position towards Novartis. The families Hoffmann and Oeri have repeatedly
stated they're committed to Roche's independence." The Full Research Report on
Novartis AG (ADR) - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/9b6d_NVS]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North
America)